Therapeutic uses of factors which inhibit or neutralize MIF activity

Abstract

The present invention relates to methods of treating disorders related to cellular overproliferation comprising neutralizing the production or activity of macrophage migration inhibitory factor (MIF). The invention also relates to therapeutic compositions comprising factors which inhibit or neutralize MIF activity, such as, MIF antisense RNA molecules and MIF monoclonal antibodies and derivatives or analogs thereof. The invention further relates to the uses of such compositions and methods for the treatment of malignancies, including, but not limited to, B and T cell lymphomas.

Description

[0001]The present application is a continuation of U.S. application Ser. No. 10 / 693,498, filed Oct. 27, 2003, now abandoned, which is a continuation of Ser. No. 08 / 738,947, filed Oct. 24, 1996, now U.S. Pat. No. 6,774,227, which is a continuation-in-part of U.S. patent application Ser. No. 08 / 462,350, filed Jun. 5, 1995, now abandoned, which is a continuation-in-part of U.S. patent application Ser. No. 08 / 243,342, filed May 16, 1994, now abandoned, which is a continuation-in-part of U.S. patent application Ser. No. 08 / 063,399, filed May 17, 1993 (now abandoned), each of which is incorporated herein by reference in their entirety.1. INTRODUCTION[0002]The present invention relates to methods of treating disorders related to cellular overproliferation comprising neutralizing the production or activity of macrophage migration inhibitory factor (MIF). The invention also relates to therapeutic compositions comprising factors which inhibit or neutralize MIF activity, such as, MIF antisense...

AI Technical Summary

Problems solved by technology

Until very recently, however, the lack of a reliable source of purified MIF has continued to hamper investigation of the precise biological profile of this molecule.

Images